Investors in advanced therapies emphasize that biotech startups must demonstrate a clear path to clinical success, particularly in areas such as oncology, neurology and obesity.[1] Recent market conditions have made funding difficult, with traditional venture capitalists favoring late-stage companies with proven clinical assets and the potential for $1 billion in first-year sales.[1] Still, companies like Mirador Therapeutics and BioAge Labs raised $400 million and $170 million respectively in March of this year.[1] Successfully overcoming the "valley of death" requires early planning, adaptability and building trust with investors.[1] Startups should use non-traditional funding sources, strategic partnerships and innovative compensation models.[1][2] Non-dilutive financing, such as grants, allows to maintain control over the company without diluting the ownership stake.[2] Investors see the current slowdown as an opportunity to invest in undervalued assets with high potential.[1]